XingImaging Announces Alzheimer's Disease PET Imaging in Mainland China.
XingImaging has initiated a Florbetapir PET radiotracer production network and PET acquisition to support clinical studies in China for Eisai Inc. on their MissionAD trial, global Phase 3 program for the Beta-site amyloid precursor protein cleaving enzyme (BACE) inhibitor elenbecestat (E2609).
XingImaging is actively incorporating into their network the production of additional tracers targeting neurodegenerative disorders. They expect the availability of these tracers in China by 4Q 2018 for use in clinical research. XingImaging also anticipates expanding their current production network from five sites in 2018 to 10 sites in 2019.
'XingImaging is committed to production of radiotracers to support clinical trials in China and we are delighted to be working with Eisai as our inaugural PET imaging multi-center clinical trial. Most importantly, XingImaging's PET capabilities will help enable AD patients in China to participate in clinicals trial testing novel AD investigational therapeutics moving forward,' says Gilles Tamagnan, CEO XingImaging, LLC
About XingImaging LLC: A privately held Delaware limited liability company (LLC) based in New Haven, CT. XingImaging LLC is a specialty radiopharmaceutical production and PET acquisition CRO formed in January 2018 to fill a unique clinical research role in China. XingImaging, is a US based biomarker imaging company focused on conducting radiopharmaceutical imaging trials in China. With well-established study teams in China and the US, XingImaging works in collaboration with biotech and pharmaceutical companies for the testing and advancement of therapeutics through brain imaging.
Forward Looking Statements: Certain information set forth in this presentation contains 'forward-looking information', including 'future oriented financial information' and 'financial outlook', under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future MandA activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company's current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
|Printer friendly Cite/link Email Feedback|
|Publication:||The President Post (Jakarta, Indonesia)|
|Date:||Sep 30, 2018|
|Previous Article:||Nano Dimension Continues Asia-Pacific Expansion with New Strategic Cooperation Agreement.|
|Next Article:||Hanergy Registers 30 Times Mid-year Profit Compared to Last Year.|